Health Improvement Scotland and NHS Scotland Logos

Scottish Palliative Care Guidelines print pdf

News and Updates

 

MHRA alert regarding Hyoscine Butylbromide (Buscopan) Injection

Following consideration of the MHRA alert regarding Hyoscine butylbromide (Buscopan) injection: risk of serious adverse effects in patients with underlying cardiac disease by the Palliative Care Development Group in consultation with specialist colleagues from palliative medicine and cardiology no action will be taken to amend the Palliative Care Guidelines which refer to this drug, namely:

Bowel Obstruction

Drug Administration Table: Unlicensed Routes

Renal Disease in the Last Days of Life

Anticipatory Prescribing

Care in the Last Days of Life

When considering drug intervention it is the responsibility of all professionals to exercise clinical judgement in the management of individual patients.  This should include taking into consideration changes to SPC content and relevant MHRA alerts when reaching a decision about the risks and benefits of individual clinical care.

 

Palliative Care Bulletin November 2017

The research bulletin for November is now available.